ClinicalTrials.gg
RecruitingNCT02719314Rh-GIOPUpdated Oct 29, 2026

Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis

An observational study in Osteoporosis and Inflammatory Rheumatism, sponsored by Prof Dr Frank Buttgereit. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Prof Dr Frank Buttgereit · Observational

How we know

From the registry’s dates

  • Started Dec 2015; still recruiting 10 years 11 months later.
Updated Oct 29, 2026Results publication addedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Osteoporosis with a site in Germany — 7 open to participants now, 12 under way, none of them phase 3. Osteoporosis · Germany.

Planned enrollment
Largest of 17
10,000 · median 144
Started
2015
with 1 other
Observational
17 of 55
4 open now
Primary completion
2029-07
later than 11 of 11 live
Registered
38th of 55
by date

Among the 55 studies in Osteoporosis with a site in Germany, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2015, is one of 17 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 38th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

7 of the 55 studies in Osteoporosis with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Osteoporosis with a site in Germany, or all of them as a file.
02

Study summary

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis). The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.

Read the detailed description

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis), since GIOP is counted among the two most important adverse effects of glucocorticoid therapy, by both rheumatologists and patients. The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.

03

Conditions studied

  • Osteoporosis
  • Inflammatory Rheumatism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with chronic inflammatory rheumatic diseases or psoriasis treated with glucocorticoids

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Every patient has to fulfill the following inclusion criteria:

  • patients with (control group: without) a diagnosis of a chronic inflammatory rheumatic disease or psoriasis
  • patients who (not for control groups) have/had already a therapy, or patients in which the implementation of a new long-term GC therapy is expected
  • patients who, according to the Dachverband Osteologie (DVO, Germany) guidelines, attend our osteoporosis and bone metabolism outpatient consultation hours or are referred by the hospital wards of the Charité for diagnosis, treatment or follow-up
  • capability to understand the patient information
  • consent to participation in the project and storage of data

Exclusion criteria

Exclusion Criteria:

If any of the following exclusion criteria is true, the patient must not be included in this study:

  • alcohol, medication and/or drug addiction
  • severe psychiatric diseases limiting the comprehension of the project plan and the study protocol (persons incapable of giving )
  • pregnant and lactating patients
  • patients incapable of giving informed consent for any reason
  • prisoners and all persons who are committed to an institution due to an official or judicial order
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
14 Years
Patient registry
Yes

Groups and cohorts

  • Rh-GIOP(A)

    Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases

    Drug: Glucocorticoid treatment

  • Rh-GIOP(B)

    Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis

    Drug: Glucocorticoid treatment

  • Rh-GIOP(C)

    Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment

Interventions

  • DrugGlucocorticoid treatment

    Glucocorticoid treatment

    Also known as: prednis(ol)one, methylprednisolone

06

What researchers measure

Primary outcomes

  1. Bone mineral density

    T-score (measured by DEXA; statistical evaluation on group levels, lower values are considered as being more dangerous)

    Time frame: 2 - 5 years

Secondary outcomes

  1. Mean daily glucocorticoid dosage

    Mean daily dosage in milligram prednisone equivalent per day (measured by questionnaire; averaged values are calculated; statistical evaluation on group levels, higher values are considered as being more dangerous)

    Time frame: 1 day - 25 years

  2. Cumulative glucocorticoid dosage

    Cumulative glucocorticoid dosage in gram (measured by questionnaire; summed values are calculated; statistical evaluation on group levels, higher values are considered as being more dangerous)

    Time frame: at least 1 day - 25 years

  3. Duration of glucocorticoid dosage

    Duration of glucocorticoid therapy in days (measured by questionnaire; statistical evaluation on group levels; higher values are considered as being more dangerous)

    Time frame: from 1 day - 25 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL, Buttgereit F. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides-Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells. 2022 Feb 4;11(3):536. doi: 10.3390/cells11030536. PubMed 35159345 ↗
  • Palmowski A, Boyadzhieva Z, Nielsen SM, Muche B, Hermann S, Boers M, Bliddal H, Christensen R, Wiebe E, Buttgereit F. Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2023 Jun 7;25(1):98. doi: 10.1186/s13075-023-03083-x. PubMed 37287080 ↗
  • Palmowski A, Schmajuk G, Yazdany J, Katz P, Li J, Stovall R, Kersey E, Nielsen SM, Christensen R, Bliddal H, Boyadzhieva Z, Schneider U, Alexander T, Muche B, Hermann S, Wiebe E, Buttgereit F. Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study. Mayo Clin Proc. 2024 Jul;99(7):1046-1057. doi: 10.1016/j.mayocp.2023.12.008. Epub 2024 May 16. PubMed 38752948 ↗
  • Hermann S, Palmowski A, Hermann KGA, Muche B, Lepretre N, Alexander T, Boyadzhieva Z, Kronke G, Hoff P, Wiebe E, Buttgereit F. Elevated uric acid is associated with a low bone mineral density in pre- but not post-menopausal women with rheumatoid arthritis: a pilot study. Rheumatol Int. 2024 Nov;44(11):2497-2504. doi: 10.1007/s00296-024-05655-9. Epub 2024 Jul 29. PubMed 39073429 ↗
  • Wiebe E, Schilling EC, Huscher D, Palmowski A, Boyadzhieva Z, Hermann S, Muche B, Picazo ML, Kronke G, Hiepe F, Alexander T, Buttgereit F. Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases. Arthritis Res Ther. 2025 Jul 28;27(1):158. doi: 10.1186/s13075-025-03610-y. PubMed 40722203 ↗
  • Wiebe E, Huscher D, Schaumburg D, Palmowski A, Hermann S, Buttgereit T, Biesen R, Burmester GR, Palmowski Y, Boers M, Stone JH, Dejaco C, Buttgereit F. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis. 2022 Aug 11;81(9):1313-1322. doi: 10.1136/annrheumdis-2022-222339. PubMed 35680387 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2015 (actual). Primary completion is estimated for Jul 2029, 163 months after the start.

Of 115 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 163 months is above that.

Counting every sponsor, half of 126 studies reached it within 51 months; a quarter within 24 and three quarters within 97.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Nov 2025 → Jul 2029 and completion Jul 2029 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2016
First posted
Mar 25, 2016
StartActual
Dec 2015
Primary completionEst.
Jul 2029was Nov 2025
CompletionEst.
Dec 2032was Jul 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Charité University Medicine Berlin (CCM) · Berlin, Germany
Show 1 removed
  • Charité University Medicine Berlin (CCM) · Berlin, Germany
Oct 29, 2026
Primary completion
Nov 2025→Jul 2029
Oct 29, 2026
Study completion
Jul 2029→Dec 2032
Oct 29, 2026
Publications
Results publication added: Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL, Buttgereit F. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Po… PubMed 35159345 ↗; 4 more
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Publications Results publication added: Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL, Buttgereit F. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Po… PubMed 35159345 ↗; 4 more
    1 site added, 1 site removed
    Show site
    • Charité University Medicine Berlin (CCM) · Berlin, Germany
    Show 1 removed
    • Charité University Medicine Berlin (CCM) · Berlin, Germany
    Primary completion Nov 2025→Jul 2029
    Study completion Jul 2029→Dec 2032
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02719314
Lead sponsor
Prof Dr Frank Buttgereit
Responsible party
Prof Dr Frank Buttgereit (Prof Dr, Charite University, Berlin, Germany) — Sponsor-investigator
First posted
Mar 25, 2016
Start date
Dec 2015
Primary completion
Jul 2029 (estimated)
Completion
Dec 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Frank Buttgereit, Prof Dr
Contact
frank.buttgereit@charite.de
+49 30 450 513125
Edgar Wiebe, Dr
Contact
gerd.burmester@charite.de
+49 30 450 513192
Frank Buttgereit, Prof Dr
principal investigator · Charité University Medicine Berlin (CCM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion